Drug intelligence / Profile preview

A1DC + inactivated whole autologous HIV

Development stage: Preclinical
Lead developer: University of Pittsburgh
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous

Overview

An experimental HIV vaccine candidate that combines A1DC (likely an antibody or immunogen) with inactivated whole autologous HIV (patient's own inactivated HIV virus). This approach likely aims to induce broadly neutralizing antibodies against HIV as part of efforts to develop an effective preventive HIV vaccine.

Other names: autologous dendritic cell HIV vaccineSharon Riddler HIV vaccinea1DC + inactivated whole autologous HIVpgDC + inactivated whole autologous HIVa1DC + conserved HIV peptidespgDC + conserved HIV peptides

Targets

CD8A (CD8 alpha/beta Coreceptor)HIV (HIV-1 enzymes)

Beyond the preview

Go deeper on A1DC + inactivated whole autologous HIV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on A1DC + inactivated whole autologous HIV.

Explore the full profile